Potential first-in-class, once-a-day, oral treatment for refractory epilepsy. NCT10004 is being developed as a first line treatment for genetic epilepsy syndromes.
- Activity in multiple seizure models
- Expected to enter clinical trials in Q12020
GABAA α2/α3 Program
An α2/α3 selective candidate for chronic pain will be discovered through lead optimization enabled by a novel hit and new GABAA structural information.
GABAA α4β3δ Program
An α4β3δ selective candidate for genetic epilepsy syndromes will be discovered through lead optimization enabled by novel hits.